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mography ranged from (2015US)$7,221-$39,251/QALY compared to no screening. 
Also for high-risk women, combined MRI and mammography were associated 
with ICERs from (2015US)$19,288/QALY to dominant compared to mammogra-
phy alone. These results include women of any age and mammography of any 
type. ConClusions: Results suggest that annual mammography is mostly 
cost-effective when compared to no screening. According to a $100,000/QALY 
threshold, most of analyzed studies suggest that combined screening is cost-
effective in high-risk women compared to mammography alone, despite a wide 
cost-effectiveness ratios range. Notwithstanding the high level of heterogeneity 
among selected studies, this review provides a comprehensive overview of the 
cost-effectiveness of BCS and could serve in the realization of future economic 
evaluations.
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objeCtives: Glioblastoma is a most aggressive primary brain tumor. Few eco-
nomic evaluations have been performed to evaluate treatments in glioblastoma. 
The objective of this literature review was to identify the characteristics of eco-
nomic evaluations in glioblastoma and the methods used to assess their economic 
impact. Methods: A literature search was performed using MEDLINE and EMBASE 
electronic databases from January 2004 until February 2014 to identify economic 
evaluations of glioblastoma. Titles were initially screened for relevance. Then, 
abstracts of potentially relevant studies were reviewed. Finally, full-text articles were 
obtained for studies deemed relevant according to the abstract and were analyzed 
in details and relevant characteristics were extracted. Results: A total of 1,666 
potentially relevant studies were identified. After screening titles and abstracts, 105 
full-text articles were assessed according to the eligibility criteria and 14 studies 
were included. Cost-effectiveness and cost-utility analyzes were performed in 86% 
of studies. Thirty six percent of the economic evaluations used a Markov model 
and fourteen percent used a decision tree. The time horizon varied from 1 year to 
lifetime, with 57% of studies with a time horizon of more than 5 years. A large major-
ity of the economic evaluations adopted the perspective of the healthcare system 
(n= 12) and two studies reported societal perspective. The largest proportion of the 
studies compared temozolomide to several chemotherapy used in glioblastoma 
(57%), followed by bevacizumab (7%), carmustine wafer (7%). Among studies that 
reported a cost per QALY or a cost per LYG (9 studies). Among these, 29% have an 
ICER of CAD$50,000 or less, while 43% have an ICER of CAD$100,000/(QALY, LYG) 
or less. ConClusions: Despite the high level of heterogeneity among selected 
studies, this review provides a comprehensive overview of the cost-effectiveness 
of several treatments in glioblastoma and could serve in the realization of future 
economic evaluations.
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D’agostino P1, Cawston H2, Bourhis F2, Turini M1, Ruffo P1, Mcguire A3
1Helsinn Healthcare SA, Pazallo, Switzerland, 2MAPI, Nanterre, France, 3London School of 
Economics, London, UK
objeCtives: The objective was to evaluate the cost-effectiveness of an oral fixed 
combination netupitant and palonosetron (NEPA) compared with aprepitant and 
palonosetron (APPA) or palonosetron (PA) alone, to prevent chemotherapy-induced 
nausea and vomiting (CINV) in patients undergoing treatment with highly or mod-
erately emetogenic chemotherapy (HEC or MEC) in the UK. Methods: A systematic 
literature review and meta-analysis were undertaken to compare NEPA with currently 
recommended anti-emetics. Relative effectiveness was estimated over the acute (day 
1) and overall treatment (day 1-5) phases, taking complete response (CR, no emesis no 
rescue medication) and complete protection (CP, CR plus no more than mild nausea) 
as primary efficacy outcomes. A three health-state Markov cohort model, including 
CP, CR and incomplete response (no CR) for HEC and MEC, was constructed. A five 
day time horizon and UK NHS perspective were adopted. Transition probabilities 
were obtained by combining the response rates of CP and CR from NEPA trials and 
odds ratios from the meta-analysis. Utilities of 0.90, 0.70 and 0.24 were defined for CP, 
CR and incomplete response, respectively. Costs included medications and manage-
ment of CINV-related events and were obtained from the British National Formulary 
and NHS Reference Costs. The expected budgetary impact of NEPA was also evalu-
ated. Results: In HEC patients, the NEPA strategy was more effective than APPA 
(quality-adjusted life days [QALDs] of 4.263 versus 4.053; incremental emesis- and 
CINV-free days of +0.354 and +0.237 respectively) and was less costly (£66 versus £124), 
resulting in NEPA being the dominant strategy. In MEC patients, NEPA was also domi-
nant, cumulating in an estimated 0.182 extra QALDs at an incremental cost of -£7.35 
compared with PA. Introducing NEPA is estimated to provide net 5-year cumulative 
cost savings of £13,981,628. ConClusions: The results suggest NEPA is cost-effective 
for preventing CINV associated with HEC and MEC in the UK.
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four studies included the word “cost”, three “economics” and none “budget” in head-
ing or abstract. None of the publications were thorough of cost analysis (cost-effec-
tiveness, cost-utility, cost-minimizing or cost-of-illness analysis). Six HTAs and eight 
national guidelines were identified. The cost per quality adjusted life year (QALY) 
was indicated € 80.000-€ 94,000. HTAs concluded reimbursement being not recom-
mendable or no ultimate statement could be made. One pointed towards a limited 
use with caution. ConClusions: Guidelines were based on data from randomized 
clinical trials (RCTs). Health economics was not considered when guidelines were 
made. Most HTAs concluded this therapy not cost-effective or there was insufficient 
data for final conclusions. Licensing and reimbursement processes should be run 
simultaneously.
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ECoNomiC EvaluatioN for fluvEstraNt 500 mG im vErsus ExEmEstENE 
iN EGyPtiaN PatiENts With mEtastatiC brEast CaNCEr
Amin M1, Abo Taleb AM2
1astrazeneca, cairo, Egypt, 2WHO, Cairo, Egypt
objeCtives: The main objective behind conducting this study was to evaluate the 
cost-effectiveness of fluvestratnt 500 mg against, exemestene in the treatment of 
metastatic breast cancer, for the Egyptian patients, from the national fund perspec-
tive over a time horizon of 3 years. Methods: Markov chain model was applied 
with three health states. Utility data were incorporated. Costs were that of the 
fund list. Results presented in of QALYs. One-dimensional sensitivity analyses were 
employed. Results: During the three-year time horizon the total cumulative QALY 
gained for fluvestrant 500 mg was 1.58 QALY The total cumulative QALY gained for 
exemestene was a 0.43 QALY. ConClusions: The introduction of fluvestrant 500 
mg to the national fund - system was found to be cost saving based strictly from its 
perspective the model addresses both the health and economic implications of both 
drugs. The result of the study suggest that fluvestrant 500 and helping for taking the 
decision for resource allocation towards the cost saving treatment .
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objeCtives: To evaluate the cost-effectiveness of adding bevacizumab to single-
agent chemotherapy for platinum-resistant recurrent ovarian cancer. Methods: 
A decision-tree model was constructed to evaluate the cost-effectiveness of adding 
bevacizumab to standard treatment with single-agent chemotherapy (BEV + CT) as 
compared to treatment with single-agent chemotherapy alone. Transition probabili-
ties were based on findings from AURELIA, an international randomized phase III 
clinical trial and the first to evaluate the survival benefits of adding bevacizumab 
to chemotherapy for women with platinum-resistant disease. Quality-adjusted 
life-years (QALYs), progression-free survival (PFS), and costs were modeled over a 
horizon of fifteen months. Assuming a U.S. public payer perspective, incremental 
cost-effectiveness ratios (ICERs) were evaluated as the incremental cost per QALY 
gained and the incremental cost per progression-free life-year saved. To evaluate 
the robustness of our results, we performed deterministic and probabilistic sensi-
tivity analyses. Results: The ICERs associated with BEV + CT were $285,624 per 
QALY gained and $151,059 per progression-free life-year saved. Varying transition 
probabilities, costs, and utilities across the expected distribution of each parameter 
resulted in 7.2% of ICER estimates falling below the commonly accepted willingness 
to pay (WTP) threshold of $50,000/QALY gained; at a WTP threshold of $100,000/QALY 
gained, 22% of ICER estimates were cost-effective. One-way deterministic sensitivity 
analysis suggests that BEV + CT would become cost-effective at a WTP threshold of 
$50,000/QALY gained if the cost of treatment was reduced by 65%. ConClusions: 
Despite gains in QALYS and PFS, the addition of bevacizumab to single-agent chemo-
therapy for the treatment of platinum-resistant recurrent ovarian cancer would not 
be considered cost effective at a willingness to pay threshold of $50,000/QALY gained 
or $100,000/QALY gained. On a per-patient basis, individual expected benefits, risks, 
and costs associated with treatment should be taken into consideration when pre-
scribing bevacizumab.
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brEast CaNCEr
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objeCtives: The objective of this literature review was to explore the existing 
evidences regarding cost-effectiveness of breast cancer screening (BCS) tests in 
average-risk women and in high-risk women. Methods: A literature review was 
performed using the PICO method: Population consisted of women at average risk 
and at high risk for breast cancer; Intervention and Comparators were BCS tests, 
and Outcomes were incremental cost-effectiveness ratios (ICERs). The literature 
search was performed with the NHS EED filters using the electronic databases 
(MEDLINE, EMBASE and PubMed) from January 2005 until May 2015. Results: The 
literature review allowed retrieving 1,699 studies of which 39 fulfilled the eligibility 
criteria. Fourteen studies were cost-effectiveness analyses, twenty-one were cost-
utility analyses and four were both. Eighteen studies used a Markov model while 
seven studies used a decision tree. Time horizon varied from 5 years to lifetime. 
Main interventions compared were no screening, biennial mammography, annual 
mammography and annual mammography combined to MRI. For average-risk 
women, ICERs for biennial mammography varied between (2015US)$4,715-$21,747/
LYG and between (2015US)$7,548-$107,590/QALY compared to no screening, 
while ICERs for annual mammography ranged from (2015US)$24,124-$40,266/
LYG and (2015US)$69,217/QALY. For high-risk women, ICERs for annual mam-
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analysis results were consistent with the base-case findings. ConClusions: Based 
on the willingness-to-pay threshold for end-of-life cancer drugs, ceritinib may be 
considered as a cost-effective option compared with other alternatives in patients 
who have progressed or are intolerant to crizotinib.
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objeCtives: This study aims to assess the cost-effectiveness of aspirin in the pri-
mary prevention of cardiovascular events (myocardial infarction (MI) and ischemic 
stroke (IS)) and colorectal cancer (CRC) in the low-risk general population in the 
United States (US). Methods: We developed and validated a Markov model to 
predict the number of primary events (MI, IS, or CRC) in US Caucasian males 
using established age-dependent risk data from the literature. Simulations were 
performed from the US healthcare system perspective using a starting cohort of 
non-smoking, non-diabetic Caucasian males aged 40 years old with low cardiovas-
cular risk (10-year risk < 5%) and normal CRC risks for the aspirin and no-aspirin 
arms. Annual cycles were simulated until 100 years old. Cost per quality-adjusted 
life year (QALY) and cost per life year (LY) were used as the primary outcome 
measures and clinical measures, numbers needed to treat (NNT) and numbers 
needed to harm (NNH), as secondary outcome measures. A 3% discount rate was 
applied to both costs and outcomes. Both deterministic and probabilistic sen-
sitivity analyses (PSA) were performed. Results: Aspirin was found to be the 
dominant strategy in the base-case analyses. NNT and NNH were 11.1 and 13.6 
respectively. One-way sensitivity analyses showed that the findings were highly 
sensitive to rates of hemorrhagic stroke, utilities of taking pill, aspirin’s effects 
on cardiovascular events, out-of-hospital MI fatality rates, and CRC risks. PSA 
showed that when willingness-to-pay (WTP) levels were varied from USD0 to 
USD100,000 per QALY gained, aspirin is likely to be cost-effective more than 80% 
of the time. ConClusions: Aspirin is likely to be cost-effective as a primary 
preventive agent. However, the finely balanced NNT and NNH made it premature 
to recommend aspirin for primary prevention of cardiovascular and CRC events 
in low-risk Caucasian males. Resources should be channeled towards conducting 
further studies to generate more precise model inputs.
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objeCtives: To evaluate the cost-effectiveness of several sequential treatment 
strategies for chronic myeloid leukemia (CML) dependent on early molecular 
response (EMR) in the Austrian healthcare context. Methods: We adapted a pre-
viously developed Markov state-transition model to incorporate different treatment 
options (imatinib, dasatinib, nilotinib) dependent on achievement of EMR after 3 
months. We analyzed eight sequential treatment strategies using cohort simula-
tion over a lifelong time horizon. Model parameters were extracted from published 
literature, epidemiological and economic databases. We applied a 3% discount for 
health outcomes and costs. We analyzed 3 different base-case scenarios for patients 
not achieving an EMR after 3-months of imatinib treatment that were switched to a 
second-generation TKI, assuming three different effectiveness for these second-gen-
eration TKIs. Comprehensive sensitivity analyses were conducted. Results: The 
base-case analysis resulted in two non-dominated strategies: (1) imatinib, followed 
by nilotinib in case of non-achieved EMR at 3 months and dasatinib after treatment 
failure or imatinib continuation in case of achieved 3-month EMR and nilotinib 
after treatment failure; (2) nilotinib followed by its continuation in case of non-
achieved EMR at 3 months or switch to imatinib in case of achieved 3 month EMR 
and dasatinib after treatment failure. Depending on the scenario, strategy 2 resulted 
in an incremental cost-effectiveness ratio (ICER) of € 84,200/QALY, € 118,500/QALY 
or € 142,200/QALY gained compared to the baseline strategy. Remaining strategies 
were excluded due to dominance. Sensitivity analyses on generic pricing of imatinib 
showed that starting with a more potent second-generation TKI and switching to 
imatinib after an achieved EMR are the preferred strategies. ConClusions: Based 
on our analyses, we suggest nilotinib and its continuation for non-achieved EMR 
at 3 months or switch to imatinib after achieved 3-month EMR and dasatinib after 
treatment failure as a cost-effective strategy for Austria if the willingness-to pay 
threshold is at least around € 120,000/QALY.
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objeCtives: The nonavalent vaccine, by protecting against five additional onco-
genic HPV types, and nine HPV types in total (6, 11, 16, 18, 31, 33, 45, 52 and 58), is 
objeCtives: This study assessed, from a societal perspective, the cost-effective-
ness of idelalisib in combination with rituximab versus rituximab monotherapy 
for the treatment of relapsed/refractory chronic lymphocytic leukemia (CLL). CLL 
is the most common leukemia in the Western world and is clinically character-
ized by peripheral blood B-cell lymphocytosis as well as lymphadenopathy, orga-
nomegaly, cytopenias and systemic symptoms in advanced stages. Methods: The 
cost-effectiveness model adopted a lifetime horizon with three health states: 1) 
pre-progression; 2) post-progression and 3) death. Patients enter in the model in 
the pre-progression state and in each cycle (1 week length) may survive without 
progression; advance to post-progression or die. Remission was not considered 
in the model: patients in post-progression state remain there until death. Costs 
and benefits were estimated for the Portuguese setting, and discounted at 5%, 
as recommended by national guidelines. Univariate and probabilistic sensitivity 
analyses assessed the robustness of results. Clinical efficacy, safety and utility data 
were based on published evidence, while survival curves were extrapolated using a 
Weibull function. Costs estimation was based on Diagnosis Related Group database, 
national legislation and opinions of an experts’ panel. Model outputs included life 
years gained, quality-adjusted life years (QALYs), and incremental cost-effectiveness 
ratios (ICERs). Results: Survival gains as well as direct medical costs were higher 
with idelalisib in association with rituximab compared to rituximab monotherapy, 
but costs related to adverse events and end-of-life care were lower. The ICER was 
of 32.702€ /QALY and 15.935€ /LY. Results were sensitive to the discount rates with 
an undiscounted ICER of 21.942 € . For other parameters univariate analyses ranged 
between 31.228€ /QALY and 34.176 € /QALY. PSA resulted in a median willingness to 
pay of 34.801€ /QALYs or 17.000€ /LY. ConClusions: Idelalisib plus rituximab in 
the treatment of relapsed/refractory CLL, compared with rituximab plus placebo, 
is cost-effective in Portugal.
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objeCtives: HPV vaccination is recommended in France for girls aged 11 to 14 with 
a catch-up from 15 to 19 years old. Though, with a cumulative coverage rate (VCR) of 
less than 20% in girls aged 16 years old for the HPV vaccine, France has one of the 
lowest VCR in Europe. The objective of the present study is to estimate the burden 
that would be averted by reaching in France the VCR currently observed in several 
EU countries. Methods: A dynamic transmission model including a wide range 
of health and cost outcomes related to cervical, anal, vulvar, vaginal diseases and 
genital warts, was adapted to French setting. The health outcomes resulting from 
the vaccination of girls with quadrivalent HPV vaccine was assessed according to 
two different vaccine coverage rates: (i) the 2014 cumulative coverage rate in girls 
aged 16 years old of 17.2% (reported by the InVS in July 2014) (ii) a VCR of 70% as 
observed in several European countries. Results: The analyses demonstrated that 
reaching in France a VCR comparable to those observed in other European countries 
would lead to avert additional 3,873,070 genital warts, 582,339 CIN2/3, 78,899 cervical 
cancers, 1,253 vaginal cancers, 1,756 vulvar cancers, and 17,993 anal cancers (includ-
ing 4,774 in males) over 100 years. Overall, 27,222 deaths from HPV cancers could 
be averted by increasing the VCR at 70%. ConClusions: The present study shows 
that the suboptimal HPV vaccination coverage rate observed in France is linked 
with a tremendous loss of opportunity for the French population. Even though the 
applied VCR is not representative of the VCR of the entire targeted population, it 
is clear that benefits of HPV vaccination are still undermined. In a context where 
cancer is a health priority in France, combined efforts to improve HPV vaccination 
coverage rate must be pursued.
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objeCtives: To assess the cost-effectiveness of ceritinib versus alternatives in 
patients who discontinue treatment with crizotinib in anaplastic lymphoma kinase-
positive (ALK+) non-small cell lung cancer (NSCLC) from a Canadian healthcare 
perspective. Methods: A partitioned survival model with three health states (pro-
gression-free, progressive, and death) was developed to compare ceritinib versus 
other alternatives in patients with ALK+ NSCLC who were previously treated with 
an ALK inhibitor. Comparators were chosen based on reported utilization from a 
retrospective Canadian chart study; comparators were pemetrexed, best-support-
ive care (BSC) and historical control. Progression-free survival and overall survival 
for ceritinib were estimated using data from reported single-arm clinical trials 
(ASCEND-1(NCT01283516) and ASCEND-2(NCT01685060)). Survival data for compara-
tors were obtained from published clinical trials in general NSCLC population and 
from a Canadian retrospective chart study in ALK+ patients treated with crizotinib. 
Parametric models were used to extrapolate outcomes beyond trial period. Drug 
acquisition, administration, resource use and adverse event (AE) costs were obtained 
from public databases. Utilities for health states and disutilities for AEs based on 
EQ-5D were derived from literature. Incremental costs per quality-adjusted life year 
(QALY) gained were estimated. Univariate and probabilistic sensitivity analyses were 
performed. Results: Over 4 years, ceritinib was associated with 0.86 QALYs and 
total direct costs of $89,740 for post-ALK population. The incremental cost per QALY 
was $149,117 comparing ceritinib vs. BSC, $80,100 vs. pemetrexed, and 104,436 vs. 
historical controls. Additional scenarios included comparison to docetaxel with an 
ICER/QALY of $149,780 and utility scores reported from PROFILE 1007, with a reported 
ICER/QALY ranging from $62,543 vs. pemetrexed to $119,735 vs. BSC. Sensitivity 
